Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland.
Nowowiejski Psychiatric Hospital, Warsaw, Poland.
Eur Addict Res. 2020;26(3):131-140. doi: 10.1159/000506156. Epub 2020 Feb 14.
Substance use is a growing problem worldwide, and there is a great need to develop national policies addressing prevention and treatment of substance-use disorders (SUD). However, the lack of a commonly used, valuable diagnostic tool to assess the symptoms of SUDs precludes comparison of the prevalence of drug-use problems as well as the efficacy of policy strategies applied in different countries. This study was conducted to validate one of the commonly used scales the Drug Use Disorders Identification Test (the DUDIT) for use in Polish condition.
The aims of this study were to test the reliability of the DUDIT in the Polish population, to confirm the comparative stability of the factor structure of the instrument, and to verify previously proposed DUDIT cutoff scoring.
The group of drug users comprised 127 patients aged 19-40 years (mean age 30.37, SD 6.36) with a diagnosis of SUD, while the control group consisted of 533 students aged 19-25 years (mean age 20.72, SD 1.88). All participants completed the Polish version of the DUDIT. Internal consistency of the Polish version of the DUDIT was determined, and subsequently external validation was performed.
Analysis showed that the Polish version of the DUDIT was characterized by a good reliability based on Cronbach's α, with a value of 0.92. The between-group comparison revealed a significant difference between the control group and substance-dependent patients corresponding to a large effect size (Cohen's d = 3.27). The receiver-operating characteristic analysis, comparing the DUDIT score to the ICD-10 diagnosis of SUD, showed an optimal cutoff value of 7 points, with a sensitivity of 0.929 and a specificity of 0.974.
These results constitute preliminary evidence that the Polish version of the DUDIT may be a valid and reliable screening tool for drug-use disorders in the Polish population.
物质使用是一个全球性的日益严重的问题,因此需要制定解决物质使用障碍(SUD)预防和治疗的国家政策。然而,缺乏一种常用的、有价值的诊断工具来评估 SUD 的症状,这使得无法比较不同国家的药物使用问题的流行程度以及所应用的政策策略的效果。本研究旨在验证一种常用的量表——药物使用障碍识别测试(DUDIT),以确定其在波兰条件下的适用性。
本研究的目的是测试 DUDIT 在波兰人群中的可靠性,确认该工具的因子结构具有可比性,以及验证之前提出的 DUDIT 截断评分。
药物使用者组由 127 名年龄在 19-40 岁之间(平均年龄 30.37,SD 6.36)的 SUD 患者组成,而对照组由 533 名年龄在 19-25 岁之间的学生组成(平均年龄 20.72,SD 1.88)。所有参与者均完成了 DUDIT 的波兰语版本。我们对波兰语版 DUDIT 的内部一致性进行了分析,然后进行了外部验证。
分析表明,波兰语版 DUDIT 基于 Cronbach's α 具有良好的可靠性,其值为 0.92。组间比较显示,对照组和物质依赖患者之间存在显著差异,对应较大的效应量(Cohen's d = 3.27)。比较 DUDIT 评分与 ICD-10 SUD 诊断的受试者工作特征分析显示,最佳截断值为 7 分,其敏感性为 0.929,特异性为 0.974。
这些结果初步表明,波兰语版 DUDIT 可能是波兰人群药物使用障碍的一种有效且可靠的筛查工具。